As a recombinant humanized monoclonal antibody, it combined with the extracellular domain of cell-surface receptor HER2 [19] disturbed the dimerization of HER2, and blocked the downstream signaling, leading to decreased proliferation of tumor cells. Here, ERBB2 is linked to neoplasm.